Daiichi Sankyo Company, Limited (DSKYF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Daiichi Sankyo Company, Limited (DSKYF) trades at $15.95 with AI Score 55/100 (Grade B). Daiichi Sankyo Company, Limited is a global pharmaceutical firm based in Tokyo, Japan, specializing in the research, development, and marketing of innovative drugs. Market cap: $29.02B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for DSKYF: DSKYF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DSKYF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DSKYF: 2/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Daiichi Sankyo Company, Limited (DSKYF) Healthcare & Pipeline Overview
Daiichi Sankyo Company, Limited stands out in the global pharmaceutical landscape with a robust pipeline of innovative treatments, particularly in oncology and diabetes care, supported by a strong market presence and strategic collaborations.
What Is the Investment Thesis for DSKYF?
Daiichi Sankyo Company, Limited is poised for growth driven by its strong product pipeline and strategic collaborations. The company has a market capitalization of $29.02B and a P/E ratio of 17.59, indicating a solid valuation relative to its earnings potential. Key growth catalysts include the continued success of trastuzumab deruxtecan in oncology, which is expected to drive revenue growth in the coming years. Furthermore, the company's focus on expanding its diabetes and cardiovascular product offerings aligns with global health trends, as these conditions remain prevalent. With a profit margin of 12.2% and a gross margin of 68.5%, Daiichi Sankyo demonstrates operational efficiency that supports its investment in R&D. However, potential risks include regulatory challenges and competition from generic drugs, which could impact market share and profitability.
Based on FMP financials and quantitative analysis
DSKYF Key Highlights
- Market Cap of $29.02B reflects strong investor confidence in growth prospects.
- P/E ratio of 17.59 indicates attractive valuation compared to industry peers.
- Profit margin of 12.2% showcases operational efficiency and profitability.
- Gross margin of 68.5% exceeds industry average, highlighting strong pricing power.
- Dividend yield of 3.06% provides a return to shareholders amidst growth investments.
Who Are DSKYF's Competitors?
DSKYF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IPSEY Ipsen S.A. | $48.13 | +3.48% | $63.64B | 52 |
| UCBJF UCB S.A. | $295.02 | -4.09% | $56.16B | 64 |
| HOCPF HOYA Corporation | $154.58 | -8.26% | $51.71B | — |
| TKPHF Takeda Pharmaceutical Company Limited | $32.60 | +10.77% | $51.50B | 46 |
| WUXIF WuXi AppTec Co., Ltd. | $21.12 | -0.33% | $63.01B | 44 |
| ORINY Orion Oyj | $38.86 | +0.00% | $21.87B | 64 |
| MRK Merck & Co., Inc. | $126.78 | -2.15% | $313.12B | 64 |
| ORINF Orion Oyj | $82.75 | +0.00% | $11.66B | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DSKYF's Key Strengths?
- Strong focus on R&D with a diverse product pipeline.
- Established global presence with a wide distribution network.
- High gross margins indicating strong pricing power.
- Collaborative partnerships enhancing innovation and market access.
What Are DSKYF's Weaknesses?
- Dependence on a few key products for revenue generation.
- Exposure to regulatory risks in various markets.
- Challenges in maintaining competitive pricing against generics.
- Limited presence in certain emerging markets.
What Could Drive DSKYF Stock Higher?
- Continued clinical trials for trastuzumab deruxtecan expected to yield positive results.
- Expansion of diabetes product offerings to meet rising global demand.
- Anticipated regulatory approvals for new therapies in key markets.
- Strategic collaborations enhancing product development capabilities.
- Launch of new consumer healthcare products aimed at expanding market reach.
What Are the Key Risks for DSKYF?
- Regulatory challenges impacting the approval of new drugs.
- Competition from generic drugs affecting market share.
- Economic downturns leading to reduced healthcare spending.
- Supply chain disruptions impacting product availability.
What Are the Growth Opportunities for DSKYF?
- Expansion in Oncology: Daiichi Sankyo's trastuzumab deruxtecan has shown promising results in clinical trials, with the global oncology market expected to reach $300 billion by 2025. The company's innovative approach to cancer treatment positions it to capture significant market share as it expands its product offerings.
- Diabetes Care Market Growth: With the global diabetes care market projected to surpass $100 billion by 2025, Daiichi Sankyo's focus on diabetes treatments, including teneligliptin, presents a substantial growth opportunity. The increasing prevalence of diabetes worldwide drives demand for effective management solutions.
- Strategic Collaborations: The partnership with Guardant Health to develop Guardant360 CDx enhances Daiichi Sankyo's capabilities in precision medicine. This collaboration is expected to accelerate the development of companion diagnostics, which are critical for the successful commercialization of targeted therapies.
- Emerging Markets Penetration: Daiichi Sankyo aims to expand its presence in emerging markets, where healthcare spending is increasing. By leveraging its innovative product pipeline, the company can tap into new customer segments and drive revenue growth in regions with high unmet medical needs.
- Veterinary Pharmaceuticals: The global veterinary pharmaceuticals market is projected to grow significantly, offering Daiichi Sankyo an opportunity to diversify its revenue streams. The company's existing portfolio of animal health products positions it well to capitalize on this growing segment.
What Opportunities Does DSKYF Have?
- Growing demand for oncology and diabetes treatments.
- Expansion into emerging markets with increasing healthcare spending.
- Potential for new product launches and line extensions.
- Strategic collaborations to enhance product offerings.
What Threats Does DSKYF Face?
- Intense competition from established pharmaceutical companies.
- Regulatory challenges impacting product approvals.
- Market volatility affecting pricing and reimbursement.
- Potential for patent expirations leading to generic competition.
What Are DSKYF's Competitive Advantages?
- Strong R&D capabilities leading to a robust pipeline of innovative drugs.
- Established brand reputation and trust in the pharmaceutical industry.
- Strategic partnerships enhancing product development and market access.
- Diverse product portfolio mitigating risks associated with market fluctuations.
What Does DSKYF Do?
Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan. The company has evolved from a traditional pharmaceutical manufacturer into a global leader in the drug development sector, focusing on innovative therapies that address critical health needs. With a workforce of approximately 18,726 employees, Daiichi Sankyo operates in various therapeutic areas, including oncology, cardiovascular, and diabetes care. The company's flagship products include trastuzumab deruxtecan, an anti-cancer agent, and mirogabalin for pain management. Additionally, Daiichi Sankyo offers a range of medications for chronic conditions such as type 2 diabetes and osteoporosis, alongside a portfolio of vaccines and animal health products. The company has established strategic collaborations, notably with Guardant Health, to enhance its diagnostic capabilities. Daiichi Sankyo's commitment to research and development is evident in its extensive pipeline, which is designed to meet the evolving needs of patients worldwide. The company is well-positioned to leverage its expertise and innovation to capture growth opportunities in both established and emerging markets.
What Products and Services Does DSKYF Offer?
- Research and develop innovative pharmaceutical products for various therapeutic areas.
- Manufacture and market a diverse range of medications, including anti-cancer agents and diabetes treatments.
- Collaborate with other healthcare companies to enhance diagnostic capabilities.
- Provide vaccines and medications for animal health.
- Offer a portfolio of consumer healthcare products, including skincare and oral care items.
How Does DSKYF Make Money?
- Generate revenue through the sale of prescription medications and vaccines.
- Leverage R&D investments to develop new drugs and expand existing product lines.
- Engage in strategic partnerships to enhance product offerings and market reach.
- Utilize a global distribution network to access diverse markets and customer segments.
What Industry Does DSKYF Operate In?
The pharmaceutical industry is experiencing significant growth, driven by advancements in biotechnology and an increasing demand for innovative therapies. The global drug market is projected to reach approximately $1.5 trillion by 2023, with oncology and diabetes care being key growth segments. Daiichi Sankyo competes with major players such as Takeda Pharmaceutical Company Limited and UCB S.A., positioning itself through its focus on high-value therapeutics and strategic partnerships. The company's commitment to R&D and its diverse product portfolio allow it to adapt to changing market dynamics and capitalize on emerging opportunities.
Who Are DSKYF's Key Customers?
- Healthcare providers and hospitals seeking innovative treatment options.
- Patients requiring medications for chronic conditions such as diabetes and cancer.
- Veterinarians and animal health professionals using veterinary pharmaceuticals.
- Consumers purchasing over-the-counter healthcare products.
ROE 16%Key Financial Metrics
Return on equity for Daiichi Sankyo Company, Limited stands at 15.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.5%, showing how much profit it generates from its asset base. DSKYF trades at a trailing price-to-earnings ratio of 18.58, below the Healthcare sector average of ~23x. Its free cash flow yield is -1.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.42 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.4%, the inverse of the P/E and a quick read on earnings relative to price.
Daiichi Sankyo Company, Limited (DSKYF) Valuation Context
Valued at $29.02B, DSKYF is classified as a large-cap stock. Relative to its peer group, DSKYF's quantitative score of 55/100 is roughly in line with the peer average of 52/100.
Company Profile
Daiichi Sankyo Company, Limited operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Hiroyuki Okuzawa. DSKYF has traded publicly since 2008.
F-Score 5/9Financial Health
Daiichi Sankyo Company, Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.83 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Daiichi Sankyo Company, Limited revenue of about $2.15T for fiscal 2026, with EPS near $167.64. The estimate reflects 5 contributing analysts.
DSKYF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Strong focus on R&D with a diverse product pipeline.
- Established global presence with a wide distribution network.
- High gross margins indicating strong pricing power.
- Collaborative partnerships enhancing innovation and market access.
Bear Case
- Dependence on a few key products for revenue generation.
- Exposure to regulatory risks in various markets.
- Challenges in maintaining competitive pricing against generics.
- Limited presence in certain emerging markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
DSKYF Latest News
No recent news available for DSKYF.
DSKYF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DSKYF.
Price Targets
Wall Street price target analysis for DSKYF.
DSKYF MoonshotScore
What does this score mean?
The MoonshotScore rates DSKYF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Hiroyuki Okuzawa
CEO
Hiroyuki Okuzawa has extensive experience in the pharmaceutical industry, having held various leadership roles within Daiichi Sankyo since joining the company. He holds a degree in pharmacy and has a strong background in business management and operations. His leadership style emphasizes innovation and collaboration, driving the company's strategic vision.
Track Record: Under Okuzawa's leadership, Daiichi Sankyo has expanded its product pipeline significantly, particularly in oncology. His strategic decisions have led to successful collaborations, enhancing the company's market position and fostering innovation.
DSKYF OTC Market Information
The OTC Other tier includes stocks that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. These stocks may have lower liquidity and visibility compared to their listed counterparts, but they still provide opportunities for investors looking for exposure to international companies.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Lower liquidity compared to stocks listed on major exchanges, which may lead to higher volatility.
- Potential for limited access to timely financial information and disclosures.
- Regulatory risks associated with OTC trading and compliance.
- Market perception challenges due to lower visibility among investors.
- Review Daiichi Sankyo's financial reports and earnings releases.
- Analyze the company's product pipeline and market potential.
- Assess the competitive landscape and market trends.
- Investigate any recent news or developments affecting the company.
- Evaluate the company's regulatory compliance and approval history.
- Established history of operations since 1899.
- Presence in multiple international markets, indicating broad acceptance.
- Strong partnerships with other healthcare companies enhancing credibility.
Daiichi Sankyo Company, Limited Healthcare Stock: Key Questions Answered
What does Daiichi Sankyo Company, Limited do?
Daiichi Sankyo Company, Limited is a global pharmaceutical company that specializes in the research, development, manufacturing, and marketing of innovative drugs. The company offers a diverse range of products, including treatments for cancer, diabetes, and cardiovascular diseases, as well as vaccines and animal health products.
What are the main risks for DSKYF?
Daiichi Sankyo faces several risks, including regulatory challenges that could impact the approval of new drugs, competition from generic pharmaceuticals that may affect market share, and economic downturns that could lead to reduced healthcare spending. Additionally, ongoing supply chain disruptions could impact product availability and operational efficiency.
How does Daiichi Sankyo Company, Limited navigate regulatory approval processes?
Daiichi Sankyo Company, Limited has established a robust regulatory strategy to navigate the complex approval processes of agencies like the FDA and EMA. The company focuses on maintaining compliance with regulatory standards and actively engages with regulatory bodies throughout the drug development process, ensuring timely submissions and addressing any potential concerns.
What are the key factors to evaluate for DSKYF?
Daiichi Sankyo Company, Limited (DSKYF) holds an AI score of 55/100 (moderate). Not financial advice.
How frequently does DSKYF data refresh on this page?
DSKYF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DSKYF's recent stock price performance?
Daiichi Sankyo Company, Limited (DSKYF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong focus on R&D with a diverse product pipeline. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DSKYF overvalued or undervalued right now?
Valuing Daiichi Sankyo Company, Limited (DSKYF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DSKYF?
Before investing in Daiichi Sankyo Company, Limited (DSKYF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The financial data provided is based on the latest available information and may be subject to change.